Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy

Kiswahili

Tenaya Therapeutics, Inc. released a slide deck on May 17, 2026, covering results from its RIDGE-1 Phase Ib/II trial of TN-401 gene therapy. The presentation focuses on treatment for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.

The slide deck was issued by the company in connection with the clinical data review. It provides details on the ongoing study of the gene therapy candidate under the ticker TNYA on NASDAQ. No additional outcomes or participant numbers were specified in the release materials.

Makala yanayohusiana

Clinical illustration of nurse giving single-dose zilebesiran injection to hypertension patient, with blood pressure monitor showing reduction from KARDIA-2 trial results.
Picha iliyoundwa na AI

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

A single, under-the-skin dose of the investigational RNA-interference drug zilebesiran lowered blood pressure when added to standard therapy in adults whose hypertension remained uncontrolled, according to results from the global Phase 2 KARDIA-2 trial of 663 participants published in JAMA.

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.

ProQR Therapeutics presents at TIDES USA 2026

Imeripotiwa na AI

ProQR Therapeutics N.V. published its slide deck for a presentation at the TIDES USA 2026 conference. The materials were released on May 15, 2026, in connection with the company's Q1 earnings summary from May 12.

Afya

Unapproved gene therapy for longevity set to go on sale

Biashara

Intellia reports strong phase iii results for hae treatment

Asia

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.

ARS Pharmaceuticals reports strong start to 2026 in earnings call

Imeripotiwa na AI

ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Enhanced Group begins NYSE trading after SPAC merger

Imeripotiwa na AI

Enhanced Group Inc. started trading on the NYSE in early May following its combination with Paradise Acquisition Corp. The telehealth firm focuses on peptides and performance-enhancing products.

Alhamisi, 18. Mwezi wa sita 2026, 16:29:18

Oncolys president reflects on journey to world-first cancer treatment

Jumanne, 9. Mwezi wa sita 2026, 17:25:16

Longevity startup doses first patient in vision loss trial

Jumatatu, 8. Mwezi wa sita 2026, 22:24:25

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Jumatatu, 1. Mwezi wa sita 2026, 19:44:01

Bioinvent hosts kol event on ovarian cancer therapies

Jumatatu, 1. Mwezi wa sita 2026, 08:57:47

New HIV pill simplifies treatment for complex cases

Jumatatu, 1. Mwezi wa sita 2026, 07:18:16

Rallybio and Avenzo hold merger conference call

Ijumaa, 29. Mwezi wa tano 2026, 15:41:51

Virus injection halts pancreatic tumor growth in trial

Alhamisi, 28. Mwezi wa tano 2026, 16:21:52

Gene-editing drug slashes bad cholesterol 62 percent in trial

Jumamosi, 16. Mwezi wa tano 2026, 00:33:35

Caribou Biosciences presents car-t updates at healthcare conference

Alhamisi, 30. Mwezi wa nne 2026, 05:54:02

Syntara reports positive FDA feedback on amsulostat trial

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa